Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
NCT03737994 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2026-04-23 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inadequate accrual rate” | Open Targets' class: insufficient enrollment | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-11Phase 3 first posted: Guangzhou JOYO Pharma Co., Ltd, JYP0322 Tablets + Crizotinib Capsules (NCT07816380)
- 2026-07-21Also stopped (terminated): ETOP IBCSG Partners Foundation, Alectinib (NCT03445000)
- 2026-04-30Results posted on the registry: Xcovery Holdings, Inc., Phase I: X-396 (ensartinib) + Phase II: X-396 (ensartinib) (NCT01625234)
- 2025-06-11Results posted on the registry: Pfizer, Lorlatinib (NCT04362072)
- 2025-05-13Results posted on the registry: Massachusetts General Hospital, Alectinib + Bevacizumab (NCT02521051)
- 2025-05-13Also stopped (terminated): Massachusetts General Hospital, Alectinib + Bevacizumab (NCT02521051)
- 2025-05-02Phase 3 first posted: The First Affiliated Hospital of Guangzhou Medical University, Icotinib + Rezivertinib (NCT06955325)
- 2025-04-24Also stopped (withdrawn): M.D. Anderson Cancer Center, Brigatinib + Carboplatin (NCT06522360)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision